Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NAGE
HoldFallen FavouriteNiagen Bioscience, Inc. · Healthcare · United States · $260M · Avg Vol: $2M/d
38
StockRankGet insider-trade alerts
Q
78
V
46
M
7
P/E (TTM)
16.7x
ROE
21.8%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
The ticker NAGE, listed as Niagen Bioscience, Inc. in the healthcare sector, does not correspond to a clearly identifiable publicly traded company. Therefore, a specific and factual company profile cannot be accurately generated at this time.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.0M | 83.6M | 99.6M | 129.4M | 21.6% | 129.1M | 133.1M | 155.3M | 9.5% |
| EPS | -0.24 | -0.07 | 0.11 | 0.22 | 100.0% | 0.19 | 0.12 | 0.13 | -22.7% |
| Shares | 74.6M | 75.0M | 77.3M | 79.7M | +6.9% | 79.1M | — | — | — |
| Debt | 4.3M | 3.3M | 2.7M | 2.8M | -12.9% | 2.3M | — | — | — |
| Equity | 28.7M | 28.5M | 46.1M | 76.5M | 38.7% | — | — | — | — |
| Op CF | -15.1M | 7.1M | 12.1M | 13.5M | 37.7% | 5.9M | — | — | — |
| Inv CF | -0.3M | -0.1M | -0.1M | -0.3M | — | — | — | — | — |
| Fin CF | 7.7M | -90.0K | 5.4M | 6.9M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-8.4%
SMA 50SMA 200
Close
$3.04
RSI (14)
42.9
52W High
$10.52
From 52W High
0.3%
SCORE BREAKDOWN
Quality
78
ROIC
10.0%71.4
ROE
21.8%90.0
GP/Assets
77.9%95.7
Op. Margin
2.4%46.7
FCF/Assets
5.3%71.7
Piotroski
668.7
Int. Cover
50.0x89.2
D/E Ratio
0.03x76.8
Current Ratio
6.50x78.7
Value
46
P/E (TTM)
16.7x68.3
EV/EBITDA
19.5x35.9
P/FCF
45.9x32.7
P/B
3.0x46.0
P/S
1.9x69.6
Div Yield
—N/A
Momentum
7
52W High %
29%7.2
RS 6M
-50%12.7
SMA 50/200
0.70x8.1
EPS Rev 4W
-65.5%0.4
EPS Rev 12W
-68.8%0.8
EPS Improve
-47%9.8
Q Growth
-73%4.4
FUNDAMENTALS
Market Cap
$260M
P/E (Forward)
31.7x
Gross Margin
64.2%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NAGE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NAGE | Niagen Bioscience, Inc.(you) | $260M | 38 | Hold |
| ABEO | Abeona Therapeutics Inc. | $339M | 37 | Hold |
| WHWK | Whitehawk Therapeutics, Inc. | $263M | 32 | Sell |
| ANTX | AN2 Therapeutics, Inc. | $211M | 35 | Sell |
| ACOG | Alpha Cognition Inc. Common Stock | $199M | 34 | Sell |
| IKT | Inhibikase Therapeutics, Inc. | $336M | 31 | Sell |
| DTIL | Precision BioSciences, Inc. | $215M | 28 | Sell |
| PALI | Palisade Bio, Inc. | $349M | 29 | Sell |
| IMUX | Immunic, Inc. | $210M | 26 | Sell |
| ARTV | Artiva Biotherapeutics, Inc. | $542M | 36 | Hold |
Peer medians: ROE -30.7% · P/E 27.1x · Gross margin 58.1%